Evidence map›Paper›PMID 33099313›Full record

ArticleJournal of medical case reports2020

Autologous stem cell transplantation following simultaneous liver and kidney transplantation in severe amyloid light chain amyloidosis associated with multiple myeloma: a case report.

R Al-Zoairy, A Viveiros, H Zoller, S Schneeberger, G Oberhuber, E Gunsilius, H Tilg, D Wolf, J D Rudzki

Open access · goldAbstract readCase Reports
In one paragraph

Article in Journal of medical case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

R Al-ZoairyDepartment of Internal Medicine I (Gastroenterology, Hepatology, Endocrinology and Metabolism), Medical University of Innsbruck, Innsbruck, Austria.
A ViveirosDepartment of Internal Medicine I (Gastroenterology, Hepatology, Endocrinology and Metabolism), Medical University of Innsbruck, Innsbruck, Austria.
H ZollerDepartment of Internal Medicine I (Gastroenterology, Hepatology, Endocrinology and Metabolism), Medical University of Innsbruck, Innsbruck, Austria.
S SchneebergerDepartment of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Innsbruck, Austria.
G OberhuberINNPATH, Pathology Service for the Medical University of Innsbruck, Innsbruck, Austria.
E GunsiliusDepartment of Internal Medicine V (Hematology & Oncology), Medical University of Innsbruck, Innsbruck, Austria.
H TilgDepartment of Internal Medicine I (Gastroenterology, Hepatology, Endocrinology and Metabolism), Medical University of Innsbruck, Innsbruck, Austria.
D WolfDepartment of Internal Medicine V (Hematology & Oncology), Medical University of Innsbruck, Innsbruck, Austria.
J D RudzkiDepartment of Internal Medicine V (Hematology & Oncology), Medical University of Innsbruck, Innsbruck, Austria. jakob.rudzki@tirol-kliniken.at.
Innsbruck Medical University · ATUniversität Innsbruck · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe involvement of vital organs in multiple myeloma (MM) with systemic amyloid light-chain (AL) amyloidosis can lead to acute organ failure. In this case, the fear of recurrence or progression of multiple myeloma often excludes those patients from undergoing organ transplantation. Nevertheless, clinically fit patients might benefit from a different therapeutic approach. This case presentation might highlight this particular unmet need and strengthen a different treatment approach. CASE PRESENTATION: To our knowledge, we present the first case of successful simultaneous liver and kidney transplantation, followed by autologous stem cell transplantation in a 60-year-old Caucasian male patient suffering from MM (Durie-Salmon stage IIB; ISS-stage: III, RISS stage: III) with primary AL amyloidosis. Chemotherapy treatment led to end-stage kidney disease requiring dialysis. Liver failure also occurred after at least three cycles of CyBorD (bortezomib, cyclophosphamide, and dexamethasone) of induction therapy with a good hematologic response. Over three years after the initial diagnosis, the patient is reportedly showing an excellent quality of life and a complete remission. DISCUSSION AND

conclusionWe conclude that kidney and liver transplantation followed by autologous stem cell transplantation can be a treatment option for a selected group of patients with MM if AL amyloidosis is leading. In the end, the remission assessment by IMWG response criteria displayed a complete remission of MM together with complete reconstitution of organ functions (liver & renal function) as long as upfront clinical evaluation excludes significant cardiac involvement and other severe co-morbidities.

Indexed as

AmyloidosisHematopoietic Stem Cell TransplantationImmunoglobulin Light-chain AmyloidosisKidney TransplantationMultiple MyelomaHumansLiverMaleMiddle AgedNeoplasm Recurrence, LocalQuality of LifeStem Cell TransplantationTransplantation, AutologousAL amyloidosisCase reportMultiple myelomaTransplantation

Identifiers

PMID33099313
PMCPMC7585683
OpenAlexW3093683962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.